Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
A review of HER2-positive breast cancer, including etiology, diagnosis, and treatments.
Diagnosis & Disease Information
Emerging Treatments for HER2-positive Early-stage Breast Cancer: Focus on Neratinib
[OncoTargets and Therapy] This research reviews available data on the role of the HER2 pathway in breast cancer and on the different targeted agents for the treatment of patients with early-stage HER2-positive disease, with a particular focus on neratinib.
Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer
Patients with HER2-positive, HR-positive advanced breast cancer experience significantly improved progression-free survival when pertuzumab is added to first-line trastuzumab and an AI compared with trastuzumab and an AI alone, according to study findings presented at SABCS 2016.
PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab
In this presentation at SABCS 2016, researchers present an evaluation of the ability of the PAM50 HER2-enriched intrinsic subtype to predict pathologic complete response in the breast in patients who received 18 weeks of neoadjuvant dual HER2 blockade.
Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
Researchers investigated the potential of PID fluorescent nanoparticles, a novel detection technique to visualize and quantify protein in clinical samples, for quantifying HER2 protein expression in breast cancer, according to a study presented at SABCS 2016.
Guidelines issued for HER2-negative breast cancer
Evidence-based recommendations have been developed for chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer.
HER2 testing may incorrectly classify some women with breast cancer
A recent study of HER2 testing in a large cohort of women with breast cancer found important limitations in testing methods.
Guideline update leaves out novel tests in breast cancer
Massimo Cristofanilli, MD, talks about why the updated ASCO/CAP guidelines should support the use of mRNA and DNA microarray assays.
Breast cancer drug proposed for bladder cancer patients
Researchers have found amplification of HER2—a known driver of some breast cancers—in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC).
ASCO/CAP update advice on HER2 testing in breast cancer
All persons with invasive breast cancer (early stage or recurrence) should undergo testing for human epidermal growth factor receptor 2 (HER2), and at least one tumor sample should be tested for either HER2 protein expression or HER2 gene amplification.
- Loading...
Loading...
Loading... 
Loading...